Does NIVOLUMAB Cause Hypopituitarism? 455 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 455 reports of Hypopituitarism have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.5% of all adverse event reports for NIVOLUMAB.
455
Reports of Hypopituitarism with NIVOLUMAB
0.5%
of all NIVOLUMAB reports
66
Deaths
343
Hospitalizations
How Dangerous Is Hypopituitarism From NIVOLUMAB?
Of the 455 reports, 66 (14.5%) resulted in death, 343 (75.4%) required hospitalization, and 48 (10.5%) were considered life-threatening.
Is Hypopituitarism Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 455 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Hypopituitarism?
IPILIMUMAB (391)
PEMBROLIZUMAB (203)
CARBOPLATIN (89)
ATEZOLIZUMAB (71)
SOMATROPIN (67)
PACLITAXEL (64)
BEVACIZUMAB (45)
PREDNISONE (41)
DURVALUMAB (38)
LENVATINIB (34)
Which NIVOLUMAB Alternatives Have Lower Hypopituitarism Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE